title: Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary?
abstract: Maintenance treatment for patients with acute myeloid leukemia (AML) in remission has recently been controversially discussed and even abandoned by several groups. An analysis of 14 recently published multicenter trials, however, revealed the highest probabilities of relapse-free survival (RFS), in the range of 35% to 42% at 4 to 5 years, only in patients assigned to maintenance treatment as far as adult age and intent-to-treat conditions were considered. After having demonstrated a superior RFS rate from 3 years of maintenance after standard-dose consolidation compared with that from consolidation alone (P = .00004), the German AMLCG requestioned the effect of maintenance randomly compared with sequential high-dose cytosine arabinoside (Ara-C) and mitoxantrone in patients who received intensified induction treatment. The results show an advantage for maintenance treatment (RFS rate of 32%) versus the sequential Ara-C and mitoxantrone treatment (RFS rate of 25%) (P = .021). We conclude that maintenance treatment continues to substantially contribute to the management of adult patients with AML, even as part of recent strategies using intensified induction treatment, and thus appears necessary in these settings.
authors.affiliation: Department of Hematology/Oncology, University of Münster, Germany. buechnr@uni-muenster.de
authors.forename: T
authors.initials: T
authors.lastname: Büchner
authors.forename: W
authors.initials: W
authors.lastname: Hiddemann
authors.forename: B
authors.initials: B
authors.lastname: Wörmann
authors.forename: H
authors.initials: H
authors.lastname: Löffler
authors.forename: W D
authors.initials: WD
authors.lastname: Ludwig
authors.forename: C
authors.initials: C
authors.lastname: Schoch
authors.forename: T
authors.initials: T
authors.lastname: Haferlach
authors.forename: G
authors.initials: G
authors.lastname: Maschmeyer
authors.forename: P
authors.initials: P
authors.lastname: Staib
authors.forename: C
authors.initials: C
authors.lastname: Aul
authors.forename: G A
authors.initials: GA
authors.lastname: Heyll
authors.forename: A
authors.initials: A
authors.lastname: Grüneisen
authors.forename: H
authors.initials: H
authors.lastname: Rasche
authors.forename: J H
authors.initials: JH
authors.lastname: Eimermacher
authors.forename: L
authors.initials: L
authors.lastname: Balleisen
authors.forename: H J
authors.initials: HJ
authors.lastname: Pielken
authors.forename: H E
authors.initials: HE
authors.lastname: Reis
authors.forename: F
authors.initials: F
authors.lastname: Griesinger
authors.forename: A
authors.initials: A
authors.lastname: Reichle
authors.forename: M C
authors.initials: MC
authors.lastname: Sauerland
authors.forename: A
authors.initials: A
authors.lastname: Heinecke
mesh_terms: D000208:Acute Disease; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000473:pathology*; D015337:Multicenter Studies as Topic; D012074:Remission Induction